Menu Back toSession-2-Patient-Perspectives-and-Engagement-in-Benefit-Risk-Assessment-of-Opioid-Therapy

Pharmacovigilance and Risk Management Strategies Conference

NEW! The 2019 meeting will be a full three days, allowing maximum learning opportunities!


Session 2: Patient Perspectives on the Risks and Benefits of Opioid Therapy

Session Chair(s)

Robert  Pratt

Robert Pratt

  • Risk Management Analyst
  • FDA, United States
Balancing the risks of opioid therapy with the benefits is an ongoing challenge as prescription opioids continue to contribute to the US opioid crisis. This session examines the patient's understanding, attitudes, and experiences with opioids including concepts of misuse and abuse, communication of risk, and the benefit-risk perspective. Panelists will also discuss strategies to minimize risk as well as challenges with patient engagement in this setting.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the patient’s perspective, experiences, and informational needs about opioids
  • Describe a self-reported measure to identify opioid abuse and misuse behaviors
  • Understand risk assessment and mitigation strategies for the use of opioids in patients with chronic pain

Speaker(s)

Martin  Cheatle, PhD

Opioid Therapy in Patients with Chronic Pain: Present and Future of Risk Assessment and Mitigation

Martin Cheatle, PhD

  • Associate Professor of Psychology in Psychiatry
  • Perelman School of Medicine, University of Pennsylvania, United States
Karin  Coyne, PhD, MPH

Validating a Self-Report Measure of Prescription Opioid Misuse and Abuse (the POMAQ) in Patients with Chronic Noncancer Pain: Pathways to Success

Karin Coyne, PhD, MPH

  • Vice President, Research
  • Evidera, United States
Nicole  Kelly

Measuring Safety and Success: The Consumer Perspective

Nicole Kelly

  • American Chronic Pain Association, United States
Paula  Rausch, PhD, RN

Exploring Patient Knowledge, Attitudes, and Behaviors to Aid Development of the Information They Need and Want About Opioid Analgesics

Paula Rausch, PhD, RN

  • Director, Division of Health Communications, Office of Communications, CDER
  • FDA, United States